Is this another subtle message from yesterday's 8K???? I found this change in wording interesting as noted below from 8K: "Analysis of the efficacy data is still outstanding."
Item 8.01. Other Events.
On March 7, 2014, Northwest Biotherapeutics, Inc. issued a press release, in response to shareholder inquiries, reporting that it had received a recommendation from the independent Data Safety Monitoring Board that the Company’s Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer should continue as planned, based on an analysis of safety data. Analysis of the efficacy data is still outstanding. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
On March 10, 2014, Northwest Biotherapeutics, Inc. issued a press release announcing that (i) the German regulatory authority has approved a “Hospital Exemption” early access program with DCVax-L for all glioma brain cancers, including the most severe grade (Glioblastoma multiforme, Grade IV) and lower grade (less malignant) gliomas, both newly diagnosed and recurrent; and (ii) the German reimbursement authority has determined that DCVax-L treatments for glioma brain cancers are eligible for negotiating and obtaining reimbursement from the Sickness Funds of the German healthcare system. A copy of the press release is included as Exhibit 99.2 to this Current Report on Form 8-K.
News 
Market Data 
Discover 
AI
